Karyopharm Therapeutics Inc. (KPTI) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $1.92 (-72.82%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 4, 2025 | Brian Abrahams | RBC Capital | $19.00 | +889.6% |
| Oct 13, 2025 | Robert Burns | H.C. Wainwright | $15.00 | +681.3% |
| Jun 10, 2024 | Brian Abrahams | RBC Capital | $3.00 | +56.3% |
| Aug 23, 2022 | Collen Kusy | Robert W. Baird | $14.00 | +629.2% |
| Mar 10, 2022 | Brian Abrahams | RBC Capital | $8.00 | +316.7% |
Top Analysts Covering KPTI
KPTI vs Sector & Market
| Metric | KPTI | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.14 | 2.25 | 2.42 |
| Analyst Count | 7 | 8 | 19 |
| Target Upside | +141.7% | +16366.0% | +18.0% |
| P/E Ratio | -0.79 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $128M | $137M | $155M | 5 |
| 2027-12-31 | $145M | $163M | $181M | 4 |
| 2028-12-31 | $215M | $215M | $215M | 4 |
| 2029-12-31 | $318M | $352M | $401M | 3 |
| 2030-12-31 | $455M | $505M | $575M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-5.91 | $-4.37 | $-3.01 | 4 |
| 2027-12-31 | $-5.32 | $-3.18 | $-1.04 | 3 |
| 2028-12-31 | $-2.17 | $-1.17 | $-0.33 | 3 |
| 2029-12-31 | $3.05 | $3.50 | $4.13 | 1 |
| 2030-12-31 | $5.86 | $6.73 | $7.93 | 1 |
Frequently Asked Questions
What is the analyst consensus for KPTI?
The consensus among 7 analysts covering Karyopharm Therapeutics Inc. (KPTI) is Buy with an average price target of $17.25.
What is the highest price target for KPTI?
The highest price target for KPTI is $19.00, set by Brian Abrahams at RBC Capital on 2025-11-04.
What is the lowest price target for KPTI?
The lowest price target for KPTI is $3.00, set by Brian Abrahams at RBC Capital on 2024-06-10.
How many analysts cover KPTI?
7 analysts have issued ratings for Karyopharm Therapeutics Inc. in the past 12 months.
Is KPTI a buy or sell right now?
Based on 7 analyst ratings, KPTI has a consensus rating of Buy (2.14/5) with a +141.7% upside to the consensus target of $17.25.
What are the earnings estimates for KPTI?
Analysts estimate KPTI will report EPS of $-4.37 for the period ending 2026-12-31, with revenue estimated at $137M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.